{"id":"NCT01908699","sponsor":"Lung Biotechnology PBC","briefTitle":"Beraprost-314d Added-on to Tyvaso® (BEAT)","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled, Phase 3 Study to Assess the Efficacy and Safety of Oral BPS-314d-MR added-on to Treprostinil, Inhaled (Tyvaso®) in Subjects With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-05-31","primaryCompletion":"2019-02-19","completion":"2019-02-19","firstPosted":"2013-07-26","resultsPosted":"2020-02-28","lastUpdate":"2020-08-03"},"enrollment":273,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"Beraprost Sodium 314d Modified Release Tablets","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Beraprost Sodium 314d Modified Release Tablets","type":"EXPERIMENTAL"},{"label":"Placebo","type":"EXPERIMENTAL"}],"summary":"This is a multicenter, double-blind, randomized, placebo-controlled Phase 3 study, to assess the efficacy and safety of BPS-314d-MR when added-on to inhaled treprostinil (Tyvaso®)in patients with pulmonary arterial hypertension.\n\nPatients new to Tyvaso, will enter a run-in period on inhaled treprostinil until 90 days of experience is achieved to ensure drug tolerability before enrolling in the study.\n\nTreatment groups consist of one active and one placebo group. Subjects will be randomly allocated in a 1:1 ratio to one of the two treatment groups.","primaryOutcome":{"measure":"Number of Participants That Experienced Clinical Worsening","timeFrame":"up to 144 weeks","effectByArm":[{"arm":"Esuberaprost","deltaMin":8,"sd":null},{"arm":"Placebo","deltaMin":13,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":75,"countries":["United States","Israel"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":75,"n":137},"commonTop":["Headache","Dyspnoea","Nausea","Upper respiratory tract infection","Dizziness"]}}